Overview

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Patients with hematologic malignancies will receive myeloablative chemotherapy followed by stem cell rescue with bone marrow or hematopoietic peripheral blood stem cells collected by apheresis from a filgrastim- (G-CSF)-mobilized haploidentical related-donor, ie, hematopoietic peripheral blood stem cell transplant (HSCT).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Everett Meyer
Ginna Laport
Collaborator:
Doris Duke Charitable Foundation
Treatments:
Antilymphocyte Serum
Fludarabine
Fludarabine phosphate
Melphalan
Thiotepa
Thymoglobulin
Vidarabine